Comparison of intervention effects between sitagliptin combined with metformin and insulin aspart combined with metformin among patients with type 2 diabetes mellitus
YANG Liya, DU Liying, ZHANG Yadang, JIANG Lingzhi
Jinhua Centeral Hospital, Jinhua, Zhejiang 321000, China
Abstract：Objective To compare the intervention effects of sitagliptin combined with metformin and insulin aspart combined with metformin among patients with type 2 diabetes mellitus (T2DM), so as to provide the reference for optimizing blood glucose control strategies among patients with T2DM. Methods T2DM patients admitted to the department of endocrinology of Jinhua Central Hospital from January 2018 to December 2024 were selected as the research objects. According to the propensity score matching, T2DM patients were divided into sitagliptin combined with metformin group and insulin aspart combined with metformin group at a ratio of 1∶1. The basic information, capillary blood glucose, glycosylated hemoglobin blood glucose (HbA1c), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), triglyceride (TG), body mass index (BMI), systolic blood pressure (SBP) and diastolic blood pressure (DBP) of the two groups were collected by questionnaire survey, physical examination and laboratory test. The generalized estimating equation was used to analyze the changes of various indicators before and after treatment between the two groups of patients, and the intervention effect was compared. Results There were 69 cases in the sitagliptin combined with metformin group. Among these 42 cases were males, accounting for 60.87%, and 27 cases were females, accounting for 39.13%.Forty-two cases were younger than 60 years, accounting for 60.87%. There were 69 cases in the insulin aspart combined with metformin group. Among these 47 cases were males, accounting for 68.12%, and 22 cases were females, accounting for 31.88%. Forty-five cases were younger than 60 years, accounting for 65.22%. There were no statistically significant differences in gender, age, education level, smoking, drinking, vegetable and fruit intake, and disease duration between the two groups (all P>0.05). After 6 months of treatment, there was an interaction between group and time in capillary blood glucose and HbA1c in the two groups (all P<0.05), and the reduction of capillary blood glucose and HbA1c in the sitagliptin combined with metformin group was greater than that in the insulin aspart combined with metformin group. There were no statistically significant differences between groups and time in TC, HDL-C, TG, BMI, SBP, and DBP, and no interaction effect was found between groups and time (all P>0.05). Conclusion Sitagliptin combined with metformin is more effective than insulin aspart combined with metformin in controlling blood glucose among patients with T2DM.
杨丽雅, 杜厉英, 张亚当, 姜灵芝. 2型糖尿病患者西格列汀联合二甲双胍与门冬胰岛素联合二甲双胍干预效果比较[J]. 预防医学, 2025, 37(10): 1054-1058.
YANG Liya, DU Liying, ZHANG Yadang, JIANG Lingzhi. Comparison of intervention effects between sitagliptin combined with metformin and insulin aspart combined with metformin among patients with type 2 diabetes mellitus. Preventive Medicine, 2025, 37(10): 1054-1058.
[1] ZHOU Y C,LIU J M,ZHAO Z P,et al.The national and provincial prevalence and non-fatal burdens of diabetes in China from 2005 to 2023 with projections of prevalence to 2050[J].Mil Med Res,2025,12(1):1-15. [2] 龚海英,邢瑞婷,刘晓芬,等.房山区居民糖尿病患病率、知晓率、治疗率和控制率分析[J].预防医学,2024,36(7):616-621. GONG H Y,XING R T,LIU X F,et al.The prevalence,awareness,treatment and control rates of diabetes among residents in Fangshan District[J].China Prev Med J,2024,36(7):616-621.(in Chinese) [3] 中华医学会糖尿病学分会.中国糖尿病防治指南(2024版)[J].中华糖尿病杂志,2025,17(1):16-139. Chinese Diabetes Society.Guideline for the prevention and treatment of diabetes mellitus in China(2024 edition)[J].Chin J Diabetes Mellitus,2025,17(1):16-139.(in Chinese) [4] 王英杰,孙高峰,赵娥,等.2017—2021年乌鲁木齐市2型糖尿病患者管理指标分析[J].预防医学,2025,37(1):92-95. WANG Y J,SUN G F,ZHAO E,et al.Analysis of management indicators for type 2 diabetes mellitus patients in Urumqi City from 2017 to 2021[J].China Prev Med J,2025,37(1):92-95.(in Chinese) [5] WEI W,ZHAO S,FU S L,et al.The association of hypoglycemia assessed by continuous glucose monitoring with cardiovascular outcomes and mortality in patients with type 2 diabetes[J].Front Endocrinol,2019,10:1-9. [6] 李秋英. 司美格鲁肽联合二甲双胍治疗2型糖尿病的临床效果观察[J].中国现代药物应用,2025,19(12):17-21. LI Q Y.Observation on clinical effect of semaglutide combined with metformin in the treatment of type 2 diabetes mellitus[J].Chin J Mod Appl Pharm,2025,19(12):17-21.(in Chinese) [7] ROSENSTOCK J,CHUCK L,GONZÁLEZ-ORTIZ M,et al.Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-naïve type 2 diabetes[J].Diabetes Care,2016,39(3):353-362. [8] YANG Y,PENG N C,CHEN G,et al.Interaction between smoking and diabetes in relation to subsequent risk of cardiovascular events[J].Cardiovasc Diabetol,2022,21(1):1-12. [9] LI M Y,ZHANG J J,ZHA Y W,et al.A prediction model for xerostomia in locoregionally advanced nasopharyngeal carcinoma patients receiving radical radiotherapy[J].BMC Oral Health,2022,22(1):1-13. [10] 霍光强. 西格列汀与二甲双胍分别联合胰岛素对2型糖尿病患者胰岛素功能及糖脂代谢的影响[J].临床医学工程,2020,27(9):1193-1194. HUO G Q.Influence of sitagliptin or metformin combined with insulin on insulin function and glucolipid metabolism in patients with type 2 diabetes mellitus[J].Clin Medical Eng,2020,27(9):1193-1194.(in Chinese) [11] HE M Q,DENG M,WANG J Y,et al.Efficacy and tolerability of sitagliptin and metformin compared with insulin as an initial therapy for newly diagnosed diabetic patients with severe hyperglycaemia[J].Exp Ther Med,2021,21(3):1-10. [12] UTZSCHNEIDER K M,TRIPPUTI M,BUTERA N M,et al.Differential treatment effects onβ-cell function using model-based parameters in type 2 diabetes:results from the glycemia reduction approaches in diabetes:a Comparative Effectiveness Study(GRADE)[J].Diabetes Care,2025,48(4):623-631. [13] DHILLON S.Sitagliptin:a review of its use in the management of type 2 diabetes mellitus[J].Drugs,2010,70(4):489-512. [14] HU X X,LI Y L,LIU X Y.Sitagliptin phosphate ameliorates chronic inflammation in diabetes mellitus via modulating macrophage polarization[J/OL].Front Endocrinol,2025,16[2025-08-25].https://doi.org/10.3389/fendo.2025.1544684. [15] WEXLER D J,GARVEY W T,GHOSH A,et al.Weight gain was associated with worsening glycemia and cardiovascular and kidney outcomes in patients with type 2 diabetes independent of diabetes medication in the GRADE randomized controlled trial[J].Diabetes Care,2025,48(6):935-944. [16] YAN J H,YAO B,KUANG H Y,et al.Liraglutide,sitagliptin,and insulin glargine added to metformin:the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease[J].Hepatology,2019,69(6):2414-2426. [17] HERRMANN B,KASSER C,KEUTHAGE W,et al.Comparison of insulin aspart vs.regular human insulin with or without insulin detemir concerning adipozytokines and metabolic effects in patients with type 2 diabetes mellitus[J].Exp Clin Endocrinol Diabetes,2013,121(4):210-213. [18] KOZLOVSKI P.Vildagliptin-insulin combination improves glycemic control in Asians with type 2 diabetes[J].World J Diabetes,2013,4(4):151-156.
